Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $.0001 par value
-
Shares outstanding
-
10.6M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
747K
-
Shares change
-
-43.5K
-
Total reported value, excl. options
-
$2.42M
-
Value change
-
-$259K
-
Number of buys
-
5
-
Number of sells
-
-4
-
Price
-
$3.24
Significant Holders of Hepion Pharmaceuticals, Inc. - Common Stock, $.0001 par value (HEPA) as of Q4 2023
21 filings reported holding HEPA - Hepion Pharmaceuticals, Inc. - Common Stock, $.0001 par value as of Q4 2023.
Hepion Pharmaceuticals, Inc. - Common Stock, $.0001 par value (HEPA) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 747K shares
of 10.6M outstanding shares and own 7.03% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (418K shares), VANGUARD GROUP INC (160K shares), BlackRock Inc. (83K shares), GEODE CAPITAL MANAGEMENT, LLC (34.9K shares), STATE STREET CORP (15.7K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (14.6K shares), Virtu Financial LLC (12.5K shares), PNC FINANCIAL SERVICES GROUP, INC. (2.88K shares), Tower Research Capital LLC (TRC) (1.62K shares), and MORGAN STANLEY (1.45K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.